Comments (0)
Trackbacks (0)
Leave a comment
Trackback
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
Mastering the origins of conviction, one key stroke at a time
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.
Recent Posts
Categories
- $40M Offering of 5M Shares
- Alliance Defense Fund
- American Association of Clinical Chemistry
- An Expanded Market Oppurtunity
- An Objective Opinion
- Anaplastic Thyroid Cancer
- Artificial Blood
- BioMimetic Therapeutics
- Biotech Leads by Percentage in Q/2/10
- Biotechnology
- Buerger's Disease
- California Institute for Regenerative Medicine (CIRM)
- cancer
- cancer stem cells
- Cell Therapy
- Cerebral Stroke Trial
- Clinical Hold Lifted
- Clinical Trial for DCM
- Clinical Trial for multiple sclerosis-related fatigue (PMSF)
- Convertible Note Repayment
- Cord Blood Banks
- Cord Blood Stem Cells
- Cytovis
- Defense Advanced Research Projects Agency (DARPA)
- Diagnostic and Device Sector Initiatives
- DOJ's Stem Cell Brief
- Epigenetics
- EU CE Mark
- Financing
- financings
- Food and Drug Administration (FDA)
- Frozen Blood from Stored Samples
- Gene Therapy
- Growing New Replacement Joints
- Healthcare
- imetelstat (GRN163L)
- In-License of Patent Portfolio
- IND Filed
- Independent Equity Research
- induced pluripotent stem (iPS) cells
- Interim Results
- Interim results from ASTM’s US Phase 2b RESTORE-CLI trial
- iPS Cell Patents
- Motor Neurone Disease Research
- Muscular Dystrophy
- National Institute of Health(NIH)
- National Venture Capital Association (NVCA)
- Nerve Regeneration
- New Cell Lines
- New Cell Lines for Research
- New Collaboration
- New Lead Investor Google Ventures
- New Patent
- New Scientific Advisory Board Member
- New Trial Results
- NIH Funding for Clinical Trials
- Orphan Drug Status
- orthopedic regenerative medicine/biotechnology company
- Parthenogenetic Stem Cell Patent
- Patents
- Phase 2 IMPACT-DCM clinical trial extension study
- Positive Results from Phase I Study of MultiStem(R) in Heart Attack Patients
- Positive Results of Bone Marrow Regeneration Trial
- Proteins Found in Muscle Tissue
- PureGraft™ System
- Purifying Embryonic Stem Cells
- Q2 Earnings
- Quarterly Earnings
- Red Blood Cells from IVF Embryos
- Regenerative Medicine
- REGENESIS-Phase IIb stroke trial
- Registered Direct Offering
- Replicating Real Skin
- Reverse stock split
- rheumatoid arthritis
- Rod Raynovich – Contributor
- Sector Analysis
- Secured Loan Facility
- Signaling Pathways
- special protocol assessment (SPA) process
- Stem Cell Banking
- Stem Cell Data to Repair Brain Damage
- Stem Cell Gene Linked to Leukemia and Other Cancers
- Stem Cell Technology
- stem cell therapy for severe kidney disease
- Stem Cells Go to War
- strategic alliance
- Synthetic Biology
- Targeting Ischemic Diseases by Improving Blood Flow
- telomerase inhibitor drug
- The Stem Cell Therapeutic and Research Reauthorization Act of 2010
- The Vatican Response
- The Week: August 2-6/10
- Therapeutic Discovery Project
- Therapeutic Discovery Tax Credit
- Transdifferentiation Platform
- Treating corneal blindness and vision impairment
- Uncategorized
- US Army Grant for Traumatic Wounds
- US Court of Appeals for the District of Columbia
- Wall Street Letter
- Warrant Discount Offer